Cross-reference patient antibiotic allergies, previous eradication failures, and adverse reactions to evaluate safe, supervised, and contraindicated therapeutic paths for Ureaplasma species.
Comprehensive summary formatted for review with your prescribing gynecologist, urologist, or infectious disease specialist.
Ureaplasma urealyticum and parvum lack a peptidoglycan cell wall (making beta-lactam penicillins and cephalosporins completely ineffective). While asymptomatic colonization occurs in some individuals, persistent dysbiosis, pelvic discomfort, or recurrent discharge warrants shared clinical decision-making.
In couples, sexual abstinence or consistent barrier protection is critical throughout treatment and until both partners confirm clearance via PCR Test of Cure (TOC) at least 3–4 weeks after antibiotic cessation to avoid false-negative residual DNA reads.
When tetracyclines fail and fluoroquinolones are strictly contraindicated by hypersensitivity, macrolide escalations (Azithromycin 1g + 500mg daily) or streptogramins (Pristinamycin 1g QID 10d, accessible via specialized or European guidelines) represent the principal evidence-backed salvage paths.